FINWIRES · TerminalLIVE
FINWIRES

市场传闻:亚马逊计划重启真人秀节目《学徒》。

By

-- 据《华尔街日报》周四援引知情人士报道,亚马逊(AMZN)正在考虑重启真人秀节目《学徒》(The Apprentice),目前正在讨论邀请小唐纳德·特朗普出演新一季。 报道称,相关讨论尚处于早期阶段,亚马逊尚未与特朗普家族接洽。据悉,该节目由唐纳德·特朗普总统主持,曾在NBC电视台播出14季。 消息人士告诉《华尔街日报》,亚马逊于2025年3月在Prime Video上发布了原版节目的部分剧集,在特朗普赢得2024年美国总统大选后,亚马逊急于重启该节目。 亚马逊尚未回复的置评请求。 (市场闲谈新闻来源于与全球市场专业人士的对话。我们认为这些信息来自可靠来源,但可能包含传闻和猜测。我们不保证其准确性。)

Price: $261.90, Change: $-1.14, Percent Change: -0.43%

Related Articles

Mining & Metals

Agnico Eagle Q1 Record Adjusted Net Income of U$1,706 million or $3.41 per share

$AEM.TO
Treasury

TD Bank Group Issues 150 Million Swiss francs Green Bond

Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.

$TD$TD.TO
Research

Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.

$AMGN
市场传闻:亚马逊计划重启真人秀节目《学徒》。 | FINWIRES